Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Change in Account Payables (2019 - 2025)

Keros Therapeutics (KROS) has disclosed Change in Account Payables for 7 consecutive years, with -$697000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Account Payables fell 137.88% year-over-year to -$697000.0, compared with a TTM value of -$3.0 million through Dec 2025, down 1105.22%, and an annual FY2025 reading of -$3.0 million, down 1105.22% over the prior year.
  • Change in Account Payables was -$697000.0 for Q4 2025 at Keros Therapeutics, up from -$3.0 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $4.7 million in Q2 2022 and bottomed at -$5.0 million in Q3 2022.
  • Average Change in Account Payables over 5 years is -$27950.0, with a median of -$79500.0 recorded in 2023.
  • The sharpest move saw Change in Account Payables plummeted 774.73% in 2024, then surged 8678.26% in 2025.
  • Year by year, Change in Account Payables stood at $823000.0 in 2021, then fell by 27.7% to $595000.0 in 2022, then soared by 75.46% to $1.0 million in 2023, then crashed by 128.07% to -$293000.0 in 2024, then plummeted by 137.88% to -$697000.0 in 2025.
  • Business Quant data shows Change in Account Payables for KROS at -$697000.0 in Q4 2025, -$3.0 million in Q3 2025, and -$1.4 million in Q2 2025.